Literature DB >> 27669631

Th1, Th17, CXCL16 and homocysteine elevated after intracranial and cervical stent implantation.

Yanyan Tang1, Yunfei Wei1, Ziming Ye1, Chao Qin1.   

Abstract

The presence of Th1 and Th17 cells has been observed as major inducers in inflammation and immune responses associated stenting. However, there is rare data on the impact of Th1, Th17, CXCL16 and homocysteine after cerebral stent implantation. Here, we performed the statistical analysis to first evaluate the variation of the Th17and Th1 cells and their related cytokines, CXCL16 and homocysteine in the peripheral blood of patients with cerebral stenting. The flow cytometry was used to detect the proportion of Th1 and Th17 cells in peripheral blood mononuclear cells (PBMCs). The enzyme-linked immunosorbent assay was used to measure the serum concentrations of IFN-γ, IL-17 and CXCL16. Plasma homocysteine was examined by immunoturbidimetry. The level of Th1, CXCL16 and homocysteine showed an increase at 3 d, followed by the continuous decrease at 7 d and 3 months. The frequency of Th17 cells increased to a peak at three days, and subsequently decreased with a higher level than baseline. Our data revealed that the variation in Th1, Th17, CXCL16 and homocysteine in peripheral blood of patients with stenting may be implicated in inflammation after intracranial and cervical stent implantation. A better understanding of these factors will provide help for further drug design and clinical therapy.

Entities:  

Keywords:  CXCL16; Homocysteine; Th1; Th17; inflammation; stenting

Mesh:

Substances:

Year:  2016        PMID: 27669631     DOI: 10.1080/00207454.2016.1241249

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  1 in total

1.  Endovascular treatment of cerebrovascular stenosis with stent for patients with ischemic cerebrovascular disease.

Authors:  Kailong Lin; Liusheng Chen; Yang Wang; Yeqiang Xu; Guanliang Wang; Hongfang Li; Yicheng Pan; Lichun Ma; Siyi He
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.